Tumor mutational burden (TMB) is a genomic biomarker. In contrast to other biomarkers that are detected as a genomic alteration in a specific gene or via methods like immunohistochemistry, TMB is calculated. However, disagreements about calculation method, clinical indication for immunotherapy, and other factors have hindered establishment of TMB as a standardized biomarker.